 |
modified mRNA encoding UGT1A1 protein, formulated in lipid nanoparticles |
|---|---|
| Trade Name | |
| Orphan Indication | Crigler-Najjar syndrome |
| USA Market Approval | USA |
| USA Designation Date | 2016-07-05 00:00:00 |
| Sponsor | Moderna Therapeutics, Inc.;320 Bent Street;Cambridge, Massachusetts, 02141 |
